Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Publication date: Available online 21 December 2015 Source:The Lancet Author(s): Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant, Frédéric Rivière, Henri Janicot, Radj Gervais, Chrystèle Locher, Bernard Milleron, Quan Tran, Marie-Paule Lebitasy, Franck Morin, Christian Creveuil, Jean-Jacques Parienti, Arnaud Scherpereel Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial growth factor is a key mitogen for malignant pleural mesothelioma cells, therefore targeting of vascular endothelial growth factor might prove effective. We aimed to ...

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=160211169&cid=c_409_22_f&fid=40620&url=http%3A%2F%2Frss.sciencedirect.com%2Faction%2FredirectFile%3F%26zone%3Dmain%26currentActivity%3Dfeed%26usageType%3Doutward%26url%3Dhttp%253A%252F%252Fwww.sciencedirect.com%252Fscience%253F_ob%253DGatewayURL%2526_origin%253DIRSSSEARCH%2526_method%253DcitationSearch%2526_piikey%253DS0140673615012386%2526_version%253D1%2526md5%253D9fbb027ea99e1f0b0a2f3c501d751065